Oragenics raises $16.5 million, plans phase IIa trial for concussion drug

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/28/2026

1. SPY
2. AKAM
3. COST
4. META
5. NVDA
6. ZS
7. AWK
8. DRI
9. ULS
10. VEON

Go back to Oragenics raises $16.5 million, plans phase IIa trial for concussion drug
ORAGENICS (NYSE: OGEN) Delayed: 0.49 -0.01 (2%)
Previous Close $0.50    52 Week High $2.12 
Open $0.52    52 Week Low $0.33 
Day High $0.52    P/E N/A 
Day Low $0.48    EPS $-0.45 
Volume 13,348